{"name":"ThromboGenics","slug":"thrombogenics","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2012-01-01","label":"Jetrea first approved","drug":"Jetrea","drugSlug":"ocriplasmin","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Ophthalmology","slug":"ophthalmology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Jetrea","genericName":"OCRIPLASMIN","slug":"ocriplasmin","indication":"Vitreomacular traction syndrome","status":"marketed"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Ocriplasmin 125µg","genericName":"Ocriplasmin 125µg","slug":"ocriplasmin-125-g","indication":"Vitreomacular traction syndrome","status":"phase_3"}]}],"pipeline":[{"name":"Jetrea","genericName":"OCRIPLASMIN","slug":"ocriplasmin","phase":"marketed","mechanism":"Recombinant protein","indications":["Vitreomacular traction syndrome"],"catalyst":""},{"name":"Ocriplasmin 125µg","genericName":"Ocriplasmin 125µg","slug":"ocriplasmin-125-g","phase":"phase_3","mechanism":"Ocriplasmin is a recombinant microplasmin that enzymatically cleaves fibronectin and laminin in the vitreous to dissolve vitreous-retinal adhesions.","indications":["Vitreomacular traction syndrome","Symptomatic diabetic macular edema with vitreous traction","Myopic traction maculopathy"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxNclNwbTZFQWJDN2wyYzVacHFXd2UxYUpONTdKVUVGOF9IVkZYUmp1SFBWUi0tckgzcnB4aS0zTXIxZnQ0VGcweVVxNmk1N0JwTFRPajVKY3ZOcjFLbGRydWRrTGVMVHY2MGx0VVJmOVVqUzc1VGdJc0RZajNzQVUyYXI4eXJ2dE0tZEIxenhCdWNJREtxZl9obUlzelNyczR0TXRrZQ?oc=5","date":"2024-07-30","type":"pipeline","source":"Medscape","summary":"New in Neurology: Colchicine, GLP-1s, and Motor Disorders - Medscape","headline":"New in Neurology: Colchicine, GLP-1s, and Motor Disorders","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxPYjBjYnQ3ZEtVdHRWWkIxNEJZcC0yYmhhaUFTS25IZk5URXc1Y0hLN2MzdlV3bHFqY0Q3RWFWdW9rY09rRmV2Mmx6RG5Pb3Z0cEMyNk5OMmlHMl9JWXVmQzZEX2VUdVppVG5jd19LYXRTTWdhcXQxOHhkek5ZcV9vN0xyRTFOTGsxb2RqRmlMQkVrSlB6a2g4UG9jNkU?oc=5","date":"2017-11-10","type":"pipeline","source":"Fierce Biotech","summary":"Chutes & Ladders—GlaxoSmithKline CSO Vallance out, Hal Barron in - Fierce Biotech","headline":"Chutes & Ladders—GlaxoSmithKline CSO Vallance out, Hal Barron in","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxQTE1fdjlWemR2RGF5TTZWejNWNk5ZQUFNWjlhUkY1ckdPeklHX1hDZ1YyRnBLTS0yU2J5SlpoUWc1eV9zVzFYYk1ob0c4cThOeTVHRUpnN2NOOVFfc1RRb3dXS2psaERtTUJOUFR1R2ZrdXN6SjB2UWE1a1ZTdDlmTkhHWVRNdmtweGN2dWNWUDVMbTdCSVZScXNvNUc0ZmxtOXhJN3BpSE91UTFwNWw3NTMyNVFfYjd1aElOU09PTlc?oc=5","date":"2014-03-18","type":"pipeline","source":"Fierce Pharma","summary":"Why is ThromboGenics' strategic review urgent? Just look at recent Jetrea sales - Fierce Pharma","headline":"Why is ThromboGenics' strategic review urgent? Just look at recent Jetrea sales","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMic0FVX3lxTFBINTZ5ZS1fZmJ1UUJMX2pSYzc0ZHFJUzBaRHBHU21rQzlyWXprMXdQMzVRQ1E5S1VsM085QzRTeUhMb2Q3elZ5bDROWEFJcGQ2OHFNT3hJNDl6QVNKaGRjelkxYkx4Wmh6ay1oakFmekUwOEk?oc=5","date":"2013-02-04","type":"regulatory","source":"cen.acs.org","summary":"New Drug Approvals Hit 16-Year High In 2012 - cen.acs.org","headline":"New Drug Approvals Hit 16-Year High In 2012","sentiment":"positive"}],"patents":[],"drugCount":2,"phaseCounts":{"marketed":1,"phase_3":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}